Sidoti Csr Issues Optimistic Forecast for USNA Earnings

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Stock analysts at Sidoti Csr raised their Q3 2025 earnings per share (EPS) estimates for USANA Health Sciences in a research note issued on Wednesday, February 26th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will earn $0.72 per share for the quarter, up from their previous forecast of $0.70. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences' Q3 2025 earnings at $0.72 EPS, Q3 2026 earnings at $0.98 EPS and Q3 2026 earnings at $0.98 EPS.

USNA has been the topic of a number of other reports. Sidoti downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th. DA Davidson cut their price target on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Finally, StockNews.com lowered USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, February 14th.

USANA Health Sciences Price Performance

NYSE USNA traded down $0.26 during trading on Friday, reaching $29.72. 287,035 shares of the company's stock traded hands, compared to its average volume of 172,482. USANA Health Sciences has a 12-month low of $27.71 and a 12-month high of $50.32. The firm has a market cap of $566.44 million, a price-to-earnings ratio of 10.50, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. The company's 50 day simple moving average is $33.34 and its two-hundred day simple moving average is $36.41.

Remove Ads

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.49 by $0.15. The firm had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Creative Planning purchased a new stake in USANA Health Sciences during the 3rd quarter valued at about $394,000. Allspring Global Investments Holdings LLC lifted its stake in USANA Health Sciences by 14,068.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,821 shares of the company's stock valued at $1,472,000 after acquiring an additional 38,547 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in shares of USANA Health Sciences by 44.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 8,859 shares of the company's stock valued at $336,000 after acquiring an additional 2,713 shares during the last quarter. KBC Group NV increased its stake in shares of USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company's stock worth $40,000 after acquiring an additional 519 shares during the period. Finally, Royce & Associates LP raised its holdings in shares of USANA Health Sciences by 22.2% during the third quarter. Royce & Associates LP now owns 33,143 shares of the company's stock worth $1,257,000 after purchasing an additional 6,031 shares during the last quarter. Hedge funds and other institutional investors own 54.25% of the company's stock.

Insider Activity at USANA Health Sciences

In other news, CEO Jim Brown sold 5,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the transaction, the chief executive officer now owns 15,716 shares in the company, valued at $463,150.52. This represents a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.